Detection of primary T cell responses to drugs and chemicals in HLA-Typed volunteers: Implications for the prediction of drug immunogenicity

Toxicological Sciences

Volumn 154, Issue 2, 2016, Pages 416-429

  Faulkner, Lee ^a   Gibson, Andrew ^a   Sullivan, Andrew ^a   Tailor, Arun ^a   Usui, Toru ^a   Alfirevic, Ana ^a   Pirmohamed, Munir ^a   Naisbitt, Dean J ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug hypersensitivity; HLA; T cells

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN; CARBAMAZEPINE; FLUCLOXACILLIN; GENOMIC DNA; HLA A 31 01 ANTIGEN; HLA A 33 03 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B 15 02 ANTIGEN; HLA B 57 01 ANTIGEN; HLA B 58 01 ANTIGEN; HLA B ANTIGEN; HLA DQA1 02 01 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 07 01 ANTIGEN; HLA DRB1 15 01 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 2; LAPATINIB; LUMIRACOXIB; MELAGATRAN; OXIPURINOL; PIPERACILLIN; TICLOPIDINE; UNCLASSIFIED DRUG; XIMELAGATRAN; 4-NITROSOSULFAMETHOXAZOLE; CYTOKINE; SULFAMETHOXAZOLE;

ANTIGEN SPECIFICITY; ARTICLE; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE BANK; ADULT; ANALOGS AND DERIVATIVES; BIOBANK; CELL CULTURE; CELL PROLIFERATION; COCULTURE; DRUG EFFECTS; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; PROCEDURES; RISK ASSESSMENT; TOXICITY TESTING; YOUNG ADULT;

ADULT; BIOLOGICAL SPECIMEN BANKS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; RISK ASSESSMENT; SULFAMETHOXAZOLE; T-LYMPHOCYTES; TOXICITY TESTS; YOUNG ADULT;

EID: 85020948992     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw177     Document Type: Article

References (64)

1. Adam, J., Pichler, W. J., and Yerly, D. (2011). Delayed drug hypersensitivity: models of T-cell stimulation. Brit. J. Clin. Pharm 71, 701-707
2. Adam, J., Eriksson, K. K., Schnyder, B., Fontana, S., Pichler, W. J., and Yerly, D. (2012). Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur. J. Immunol. 42, 1706-1716
3. Adam, J., Wuillemin, N., Watkins, S., Jamin, H., Eriksson, K. K., Villiger, P., Fontana, S., Pichler, W. J., and Yerly, D. (2014). Abacavir induced T cell reactivity from drug naive individuals shares features of allo-immune responses. PLoS One 9, e95339
4. Alfirevic, A., Vilar, F. J., Alsbou, M., Jawaid, A., Thomson, W., Ollier, W. E., Bowman, C. E., Delrieu, O., Park, B. K., and Pirmohamed, M. (2009). TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. Pharmacogenomics 10, 531-540
5. Alfirevic, A., Gonzalez-Galarza, F., Bell, C., Martinsson, K., Platt, V., Bretland, G., Evely, J., Lichtenfels, M., Cederbrant, K., French, N., et al. (2012). In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 4, 51
6. Almeida, C. A., Martin, A. M., Nolan, D., Lucas, A., Cameron, P. U., James, I., Phillips, E., and Mallal, S. (2008). Cytokine profiling in abacavir hypersensitivity patients. Antivir. Ther. 13, 281-288
7. Bell, C. C., Faulkner, L., Martinsson, K., Farrell, J., Alfirevic, A., Tugwood, J., Pirmohamed, M., Naisbitt, D. J., and Park, B. K. (2013). T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. Chem. Res. Toxicol. 26, 759-766
8. Castrejon, J. L., Berry, N., El-Ghaiesh, S., Gerber, B., Pichler, W. J., Park, B. K., and Naisbitt, D. J. (2010). Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J. Allergy Clin. Immunol. 125, 411-418
9. Chessman, D., Kostenko, L., Lethborg, T., Purcell, A. W., Williamson, N. A., Chen, Z., Kjer-Nielsen, L., Mifsud, N. A., Tait, B. D., Holdsworth, R., et al. (2008). Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28, 822-832
10. Coulter, E. M., Jenkinson, C., Wu, Y., Farrell, J., Foster, B., Smith, A., McGuire, C., Pease, C., Basketter, D., King, C., et al. (2008). Activation of T-cells from allergic patients and volunteers by p-phenylenediamine and Bandrowski's base. J. Invest. Dermatol. 128, 897-905
11. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486
12. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R., et al. (2009). HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819
13. Dietz, L., Esser, P. R., Schmucker, S. S., Goette, I., Richter, A., Schnolzer, M., Martin, S. F., and Thierse, H. J. (2010). Tracking human contact allergens: from mass spectrometric identification of peptide-bound reactive small chemicals to chemical-specific naive human T-cell priming. Toxicol. Sci. 117, 336-347
14. El-Ghaiesh, S., Monshi, M. M., Whitaker, P., Jenkins, R., Meng, X., Farrell, J., Elsheikh, A., Peckham, D., French, N., Pirmohamed, M., et al. (2012). Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J. Pharmacol. Exp. Ther. 341, 597-610
15. Engler, O. B., Strasser, I., Naisbitt, D. J., Cerny, A., and Pichler, W. J. (2004). A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 197, 47-56
16. Farrell, J., Naisbitt, D. J., Drummond, N. S., Depta, J. P., Vilar, F. J., Pirmohamed, M., and Park, B. K. (2003). Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J. Pharmacol. Exp. Ther. 306, 229-237
17. Farrell, J., Lichtenfels, M., Sullivan, A., Elliott, E. C., Alfirevic, A., Stachulski, A. V., Pirmohamed, M., Naisbitt, D. J., and Park, B. K. (2103) Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. J. Allergy Clin. Immunol. 132, 493-495
18. Faulkner, L., Martinsson, K., Santoyo-Castelazo, A., Cederbrant, K., Schuppe-Koistinen, I., Powell, H., Tugwood, J., Naisbitt, D. J., and Park, B. K. (2012). The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol. Sci. 127, 150-158
19. Gibson, A., Ogese, M., Sullivan, A., Wang, E., Saide, K., Whitaker, P., Peckham, D., Faulkner, L., Park, B. K., and Naisbitt, D. J. (2014). Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function. J. Immunol. 192, 2611-2621
20. Gonzalez-Galarza, F. F., Takeshita, L. Y., Santos, E. J., Kempson, F., Maia, M. H., Silva, A. L., Silva, A. L., Ghattaoraya, G. S., Alfirevic, A., Jones, A. R., et al. (2015). Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acid Res. 28, D784-D788
21. Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122
22. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P., Lin, Y. L., Lan, J. L., Yang, L. C., Hong, H. S., et al. (2005). HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102, 4134-4139
23. Illing, P. T., Vivian, J. P., Purcell, A. W., Rossjohn, J., and McCluskey, J. (2013). Human leukocyte antigen-associated drug hypersensitivity. Curr. Opin. Immunol. 25, 81-89
24. Jahn, S., Faber, H., Zazzeroni, R., and Karst, U. (2012). Electrochemistry/mass spectrometry as a tool in the investigation of the potent skin sensitizer p-phenylenediamine and its reactivity toward nucleophiles. Rapid Commun. Mass Spectrom. 26, 1453-1464
25. Jenkins, R. E., Yaseen, F. S., Monshi, M. M., Whitaker, P., Meng, X., Farrell, J., Hamlett, J., Sanderson, J. P., El-Ghaiesh, S., Peckham, D., et al. (2013). b-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific Tlymphocyte responses in multiallergic patients with cystic fibrosis. Chem. Res. Toxicol. 26, 963-975
26. Jenkinson, C., Jenkins, R. E., Aleksic, M., Pirmohamed, M., Naisbitt, D. J., and Park, B. K. (2010). Characterization of pphenylenediamine-albumin binding sites and T-cell responses to hapten-modified protein. J. Invest. Dermatol. 130, 732-742
27. Karton, A., and Martin, J. M. (2012). Comment on "Revised electron affinity of SF6 from kinetic data. J. Chem. Phys. 136, 197101
28. Kim, S. H., Saide, K., Farrell, J., Faulkner, L., Tailor, A., Ogese, M., Daly, A. K., Pirmohamed, M., Park, B. K., and Naisbitt, D. J. (2015). Characterization of amoxicillin-and clavulanic acidspecific T cells in patients with amoxicillin-clavulanateinduced liver injury. Hepatology 62, 887-899
29. Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., Carlsson, S., Cederbrant, K. E., Gibson, N. J., Armstrong, M., et al. (2008). Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195
30. Ko, T. M., Chung, W. H., Wei, C. Y., Shih, H. Y., Chen, J. K., Lin, C. H., Chen, Y. T., and Hung, S. I. (2011). Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128, 1266-1276
31. Kuechler, P. C., Britschgi, M., Schmid, S., Hari, Y., Grabscheid, B., and Pichler, W. J. (2004). Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 59, 613-622
32. Lancaster, A. K., Single, R. M., Solberg, O. D., Nelson, M. P., and Thomson, G. (2007). PyPop update-a software pipeline for large-scale multilocus population genomics. Tissue Antigens 69, 192-197
33. Lichtenfels, M., Farrell, J., Ogese, M. O., Bell, C. C., Eckle, S., McCluskey, J., Park, B. K., Alfirevic, A., Naisbitt, D. J., and Pirmohamed, M. (2014). HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient. Chem. Res. Toxicol. 27, 175-177
34. Lin, C. H., Chen, J. K., Ko, T. M., Wei, C. Y., Wu, J. Y., Chung, W. H., Chen, S. Y., Liao, Y. D., Hung, S. I., and Chen, Y. T. (2015). Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drugspecific T cells and molecular interaction. J. Allergy Clin. Immunol. 135, 1063-1065
35. Lucas, A., Lucas, M., Strhyn, A., Keane, N. M., McKinnon, E., Pavlos, R., Moran, E. M., Meyer-Pannwitt, V., Gaudieri, S., D'Orsogna, L., et al. (2015). Abacavir-reactive memory T cells are present in drug naive individuals. PLoS One 10, e0117160
36. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732
37. Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J., Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579
38. Martin, S. F., Esser, P. R., Schmucker, S., Dietz, L., Naisbitt, D. J., Park, B. K., Vocanson, M., Nicolas, J. F., Keller, M., Pichler, W. J., et al. (2010). T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol. Life Sci. 67, 4171-4184
39. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavíciute, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I., et al. (2011). HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143
40. Monshi, M. M., Faulkner, L., Gibson, A., Jenkins, R. E., Farrell, J., Earnshaw, C. J., Alfirevic, A., Cederbrant, K., Daly, A. K., French, N., et al. (2013). Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57, 727-739
41. Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., Burkhart, C., Cribb, A. E., Pichler, W. J., and Park, B. K. (2001). Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 133, 295-305
42. Naisbitt, D. J., Britschgi, M., Wong, G., Farrell, J., Depta, J. P., Chadwick, D. W., Pichler, W. J., Pirmohamed, M., and Park, B. K. (2003). Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol. 63, 732-741
43. Naisbitt, D. J., Farrell, J., Gordon, S. F., Maggs, J. L., Burkhart, C., Pichler, W. J., Pirmohamed, M., and Park, B. K. (2002). Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complexrestricted antigen presentation. Mol. Pharmacol. 62, 628-637
44. Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M., and Roujeau, J. C. (2004). Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209-1215
45. Pearce, R. E., Uetrecht, J. P., and Leeder, J. S. (2005). Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab. Dispos. 33, 1819-1826
46. Pearce, R. E., Vakkalagadda, G. R., and Leeder, J. S. (2002). Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab. Dispos. 30, 1170-1179
47. Phillips, E. J., Chung, W. H., Mockenhaupt, M., Roujeau, J. C., and Mallal, S. A. (2011). Drug hypersensitivity: pharmacogenetics and clinical syndromes. J. Allergy Clin. Immunol. 127, S60-S66
48. Schnyder, B., Burkhart, C., Schnyder-Frutig, K., von Greyerz, S., Naisbitt, D. J., Pirmohamed, M., Park, B. K., and Pichler, W. J. (2000). Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164, 6647-6654
49. Sieben, S., Kawakubo, Y., Al Masaoudi, T., Merk, H. F., and Blomeke, B. (2002). Delayed type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J. Allergy Clin. Immunol. 109, 1005-1011
50. Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J., and Paulding, C. A. (2010). A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711-714
51. Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J., King, K. S., Whittaker, J. C., Mooser, V. E., Preston, A. J., Stein, S. H., et al. (2011). HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667-673
52. Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Chen, P., Lin, S. Y., Chen, W. H., Konyoung, P., Khunarkornsiri, U., Auvichayapat, N., Pavakul, K., et al. (2010). Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926-930
53. Uetrecht, J., and Naisbitt, D. J. (2013). Idiosyncratic adverse drug reactions: current concepts. Pharmacol. Rev. 65, 779-808
54. Vitezica, Z. G., Wolkenstein, P., Lonjou, C., Eliaszewicz, M., Sicard, X., Roujeau, J. C., and Hovnanian, A. (2008). No association between HLA-B and cutaneous reactions to sulphonamides in human immunodeficiency virus-infected patients. Br. J. Dermatol. 159, 501-503
55. Wei, C. Y., Chung, W. H., Huang, H. W., Chen, Y. T., and Hung, S. I. (2012). Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129, 1562-1569
56. Whitaker, P., Meng, X., Lavergne, S. N., El-Ghaiesh, S., Monshi, M., Earnshaw, C., Peckham, D., Gooi, J., Conway, S., Pirmohamed, M., et al. (2011). Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J. Immunol. 187, 200-211
57. White, K. D., Chung, W. H., Hung, S. I., Mallal, S., and Phillips, E. J. (2015). Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J. Allergy Clin. Immunol. 136, 219-234
58. Wu, Y., Farrell, J., Pirmohamed, M., Park, B. K., and Naisbitt, D. J. (2007). Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J. Allergy Clin. Immunol. 119, 973-981
59. Wuillemin, N., Terracciano, L., Beltraminelli, H., Schlapbach, C., Fontana, S., Krähenbühl, S., Pichler, W. J., and Yerly, D. (2014). T cells infiltrate the liver and kill hepatocytes in HLAB(*) 57:01-associated floxacillin-induced liver injury. Am. J. Pathol. 184, 1677-1682
60. Wuillemin, N., Adam, J., Fontana, S., Krähenbühl, S., Pichler, W. J., and Yerly, D. (2013). HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J. Immunol. 190, 4956-4964
61. Yaseen, F., Saide, K., Kim, S.-H., Monshi, M., Tailor, M., Wood, S., Meng, M., Jenkins, R., Faulkner, L., Daly, A. K., et al. (2015). Promiscuous T-cell responses to drugs and drug-haptens. J. Allergy Clin. Immunol. 136, 474-476
62. Yun, J., Mattsson, J., Schnyder, K., Fontana, S., Largiadèr, C. R., Pichler, W. J., and Yerly, D. (2013). Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin. Exp. Allergy 43, 1246-1255
63. Yun, J., Marcaida, M. J., Eriksson, K. K., Jamin, H., Fontana, S., Pichler, W. J., and Yerly, D. (2014). Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J. Immunol. 192, 2984-2993
64. Zhang, Y., Wang, J., Zhao, L. M., Peng, W., Shen, G. Q., Xue, L., Zheng, X. X., He, X. J., Gong, C. Y., and Miao, L. Y. (2011). Strong association between HLA-B*1502 and carbamazepineinduced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur. J. Clin. Pharmacol. 67, 885-887